Biomedicine & Pharmacotherapy (Jan 2019)

Exendin-4 promotes actin cytoskeleton rearrangement and protects cells from Nogo-A-Δ20 mediated spreading inhibition and growth cone collapse by down-regulating RhoA expression and activation via the PI3K pathway

  • Fei Zhao,
  • jianwei Li,
  • Renjie Wang,
  • Huiyou Xu,
  • Ke Ma,
  • Xianbin Kong,
  • Zhonglei Sun,
  • Xuegang Niu,
  • Jipeng Jiang,
  • Baohu Liu,
  • Bo Li,
  • Feng Duan,
  • Xuyi Chen

Journal volume & issue
Vol. 109
pp. 135 – 143

Abstract

Read online

Exendin-4 is a protein of the GLP-1 family currently used to treat diabetes. Recently, a greater number of biological properties have been associated with the GLP-1 family. Our data shows that exendin-4 treatment significantly increases the cytoskeleton rearrangement, which leads to an increasingly differentiated phenotype and reduced cell migration. We also found that exendin-4 could prevent SH-SY5Y and PC12 cells from Nogo-A-Δ20 mediated spreading inhibition and neurite collapse. Western blot analysis indicated that exendin-4 treatment both reduced the expression and activation of RhoA via the PI3K signaling pathway. These data suggest that exendin-4 may protect nerve regeneration by preventing the inhibition of Nogo-A via down-regulating RhoA expression and activation.

Keywords